Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Protiva Biotherapeutics Inc patents


Recent patent applications related to Protiva Biotherapeutics Inc. Protiva Biotherapeutics Inc is listed as an Agent/Assignee. Note: Protiva Biotherapeutics Inc may have other listings under different names/spellings. We're not affiliated with Protiva Biotherapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Protiva Biotherapeutics Inc-related inventors


Delivering crispr therapeutics with lipid nanoparticles

The present invention provides lipid particles comprising therapeutic nucleic acids such as grna that target gene expression.. . ... Protiva Biotherapeutics Inc

Novel lipid formulations for nucleic acid delivery

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (snalp) comprising a nucleic acid (such as one or more interfering rna), methods of making the snalp, and methods of delivering and/or administering the snalp.. ... Protiva Biotherapeutics Inc

Novel lipid formulations for nucleic acid delivery

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (snalp) comprising a nucleic acid (such as one or more interfering rna), methods of making the snalp, and methods of delivering and/or administering the snalp.. ... Protiva Biotherapeutics Inc

Novel lipid formulations for delivery of therapeutic agents to solid tumors

The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (snalp) comprising a nucleic acid (e.g., one or more interfering rna molecules), methods of making the snalp, and methods of delivering and/or administering the snalp (e.g., for the treatment of cancer). ... Protiva Biotherapeutics Inc

Compositions and methods for silencing hepatitis b virus gene expression

The present invention provides compositions comprising therapeutic nucleic acids such as sirna that target hepatitis b virus (hbv) gene expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating hbv infection and/or hdv infection in humans).. . ... Protiva Biotherapeutics Inc

Non-liposomal systems for nucleic acid delivery

The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (snalp) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering rna), methods of making the snalp, and methods of delivering and/or administering the snalp.. ... Protiva Biotherapeutics Inc

Liposomal apparatus and manufacturing methods

The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. ... Protiva Biotherapeutics Inc

Novel cationic lipids and methods of use thereof

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. ... Protiva Biotherapeutics Inc

Novel lipid formulations for nucleic acid delivery

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (snalp) comprising a nucleic acid (such as one or more interfering rna), methods of making the snalp, and methods of delivering and/or administering the snalp.. ... Protiva Biotherapeutics Inc

Trialkyl cationic lipids and methods of use thereof

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. ... Protiva Biotherapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Protiva Biotherapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Protiva Biotherapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###